Categories: News

Emedgene Broadens Its NLP Capabilities With Automatic Evidence Retrieval From Genomics Literature

PALO ALTO, California, April 3, 2019 /PRNewswire/ — Emedgene, provider of a fully automated genetic interpretation platform, broadens its NLP capabilities with automatic evidence retrieval from genomics literature. The enhanced NLP-based text analytics solution delivers usable insights on top of standard search results, doing much of the heavy lifting for geneticists interpreting patient cases.

“Google has moved beyond 10 blue links, with instant answers and knowledge cards. Our new NLP capabilities do the same in genomics,” explains Niv Mizrahi, Emedgene’s Co-founder & VP R&D. “For candidate variants, we select the single best piece of evidence from the literature. If the geneticist on the case wishes to investigate further, we generate insights from the literature in the context of a case, in addition to offering general search analytics.”

Analyzing literature is a critically important and time-consuming task for geneticists today. Emedgene’s knowledge base contains 5,500 unique genes with an associated disease, over 25,000 gene-disease connections and 40,000 genes. Much of this data is not available in public DBs and can be identified solely by reading the literature. 

With genomics knowledge growing exponentially, the challenge becomes separating the noise from the insights. Emedgene is taking a unique patient-focused approach which helps narrow down the results of the search to the most practical piece of evidence to share. This is achieved through a combination of NLP & machine learning algorithms that have been trained to understand the specific context of a case.

“To truly advance the field, we need cognitive AI approaches that bridge the knowledge gap, and empower labs to meet the growing demand for NGS tests,” says Einat Metzer, Emedgene’s CEO.

Emedgene will be demonstrating a variety of use cases for the novel NLP solution at ACMG in Seattle, Washington, April 3-5, booth #1229.

About Emedgene

Emedgene is the world’s first completely automated genetic interpretation platform, using AI to dramatically scale genetic interpretation. Clinical labs using Emedgene reduce time spent on interpretation and increase yield, and research organizations accelerate genomic discovery.

Read more at www.emedgene.com.

Press Contact:
Orit Livnat Levi
Director of Marketing
orit@emedgene.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/emedgene-broadens-its-nlp-capabilities-with-automatic-evidence-retrieval-from-genomics-literature-300824085.html

SOURCE Emedgene

Staff

Recent Posts

Southern Illinois Associates Selects eClinicalWorks Cloud EHR for Comprehensive Behavioral Health Tools

The psychiatry and behavioral health group to utilize practice management and patient engagement solutions to…

39 mins ago

Nym Named Among Top 25 Companies in Healthcare Software for 2024 by The Healthcare Technology Report

NEW YORK--(BUSINESS WIRE)--Nym, the leader in autonomous medical coding, today announced that it has been…

40 mins ago

LivaNova to Announce First-Quarter 2024 Results

LONDON--(BUSINESS WIRE)--#advancedcirculatorysupport--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call…

4 hours ago

Viz.ai Names Michael Herring as Chief Financial Officer

Seasoned financial leader brings experience at leading companies in healthcare and software as a service…

4 hours ago